ASH 2018 | Tislelizumab for R/R classical Hodgkin lymphoma
Yuqin Song, PhD, of Peking University Cancer Hospital & Institute, Beijing, China, presents the preliminary results of a Phase II trial investigating the immune checkpoint inhibitor tislelizumab (BGB-A317) for the treatment of relapsed/refractory classical Hodgkin lymphoma patients that have failed or were ineligible for autologous stem cell transplant (NCT03209973). Dr Song reports a best overall response rate of 86% and minimal side effects consisting of predominantly pyrexia, hypothyroidism and weight increase. Dr Song was speaking at the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA.
Get great new content delivered to your inboxSign up